Back to top
more

Henry Schein (HSIC)

(Delayed Data from NSDQ)

$70.37 USD

70.37
1,742,354

+0.14 (0.20%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $70.37 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Can Baxter (BAX) Beat Q4 Earnings on Hospital Products?

by Zacks Equity Research

Baxter International (BAX) is expected to gain from strength in Hospital Products segment on solid sales in the U.S. Fluid Systems business as well as growing demand for injectable pharmaceuticals.

    Can IDEXX (IDXX) Post a Beat in Q4 Earnings on CAG Strength?

    by Zacks Equity Research

    IDEXX Laboratories (IDXX) is poised to gain from strength in CAG Diagnostics business in Q4.

      Will WATCHMAN Boost Boston Scientific's (BSX) Q4 Earnings?

      by Zacks Equity Research

      Boston Scientific (BSX) witnesses improvement in IC arm on an innovative portfolio and robust commercial teams. The WATCHMAN platform is likely to impress with another solid quarterly performance.

        Edwards Lifesciences' (EW) THVT Likely to Drive Q4 Earnings

        by Zacks Equity Research

        Edwards Lifesciences (EW) is expected to gain from strength in THVT on continued therapy adoption across all geographies.

          Will S.E.T. Arm Drive Zimmer Biomet's (ZBH) Q4 Earnings?

          by Zacks Equity Research

          Zimmer Biomet (ZBH) poised to gain on strength in S.E.T as well as Spine & CMF segments in Q4.

            Illumina's (ILMN) Q4 Earnings to Show Growth in All Lines

            by Zacks Equity Research

            Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other revenue segments in Q4.

              Can Thermo Fisher's (TMO) Product Portfolio Up Q4 Earnings?

              by Zacks Equity Research

              Thermo Fisher (TMO) already derives synergies from the acquisition of FEI that largely adds capabilities to its analytical instruments portfolio.

                Can Invisalign Drive Align Technology's (ALGN) Q4 Earnings?

                by Zacks Equity Research

                Align Technology (ALGN) poised to gain from strength in the Invisalign space as well as Scanner and Service business in Q4.

                  Can Diagnostics Business Drive Abbott's (ABT) Q4 Earnings?

                  by Zacks Equity Research

                  Abbott (ABT) poised to gain on continued growth in Diagnostics business in Q4.

                    Can EPD & Medical Devices Drive Abbott's (ABT) Q4 Earnings?

                    by Zacks Equity Research

                    Abbott (ABT) poised to ride high on continued growth in EPD and Medical Devices business in Q4.

                      Can ResMed (RMD) Maintain Balanced Growth in Q2 Earnings?

                      by Zacks Equity Research

                      ResMed (RMD) poised to ride high on continued growth in domestic as well as overseas business in Q2.

                        Henry Schein (HSIC) Buys ABASE, Expands in Animal Health

                        by Zacks Equity Research

                        Henry Schein (HSIC) forges ahead with deals to strengthen the Global Animal Health business.

                          Patterson Companies' (PDCO) Dental Segment Shows Weakness

                          by Zacks Equity Research

                          Changing healthcare environment in the United States, unfavorable price movements and competitive dental products industry are posing challenges for Patterson Companies, Inc. (PDCO).

                            Henry Schein Buys eVetPractice, Boosts Technology & VAS Arm

                            by Zacks Equity Research

                            Henry Schein (HSIC) adopts initiatives to strengthen hold in the high-potential healthcare IT market.

                              Rising Costs Hurt Henry Schein, End-Market Trends a Tailwind

                              by Zacks Equity Research

                              Higher cost of sales and expenses hurt Henry Schein's (HSIC) gross and operating margin. However, several end market trends like demographics are likely to benefit the company.

                                Implied Volatility Surging for Henry Schein (HSIC) Stock Options

                                by Zacks Equity Research

                                Investors need to pay close attention to Henry Schein (HSIC) stock based on the movements in the options market lately.

                                  Henry Schein (HSIC) Misses Q3 Earnings, Margins Decline

                                  by Zacks Equity Research

                                  Henry Schein (HSIC) maintains stellar top-line performance in Q3, courtesy of strength in all business segments.

                                    Henry Schein (HSIC) Misses Q3 Earnings, Revenues Beat Estimate

                                    by Zacks Equity Research

                                    Henry Schein (HSIC) gains from strength in all the business segments in Q3.

                                      Can DENTSPLY (XRAY) Deliver a Beat This Earnings Season?

                                      by Zacks Equity Research

                                      In the third quarter, DENTSPLY (XRAY) is expected to witness strong growth in revenues, particularly in the dental consumables and laboratories segment.

                                        4 Medical Device Stocks to Top Q3 Earnings

                                        by Zacks Equity Research

                                        A look at how medical device players are poised for this earnings season.

                                          Key Factors to Influence PerkinElmer's (PKI) Q3 Earnings

                                          by Zacks Equity Research

                                          PerkinElmer's (PKI) divestiture of the Medical Imaging segment in the last quarter is expected to impact earnings this season.

                                            Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

                                            by Zacks Equity Research

                                            Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

                                              AmerisourceBergen (ABC) Q4 Earnings: Will it Disappoint?

                                              by Zacks Equity Research

                                              The temporary slowdown in the PharMEDium segment is expected to mar AmerisourceBergen's (ABC) bottom line in the fourth quarter

                                                Can Pharmacy Services Drive CVS Health's (CVS) Q3 Earnings?

                                                by Zacks Equity Research

                                                CVS Health (CVS) is expected to post another quarter of solid top-line performance on the back of gains from the Pharmacy Services segment.

                                                  Is Becton, Dickinson (BDX) Poised for a Beat in Q4 Earnings?

                                                  by Zacks Equity Research

                                                  Becton, Dickinson's (BDX) large base of product pipeline, industry-leading technologies and collaborations are growth propellers in Q4.